文献速递主动脉疾病

解剖固定式腹主动脉分叉型内移植物EVAR二十年单中心长期结果

Two Decades of Abdominal Aortic Endovascular Repair With the Anatomical FiXation at the Aortic Bifurcation in a Large Single-Center Experience.
PubMed 文献 · J Endovasc Ther · 2021-07-19

该单中心回顾性队列纳入1999至2016年择期行解剖固定式腹主动脉分叉型内移植物EVAR的623例AAA患者,随访至2020年。技术成功率99.4%,5年临床成功97.7%,10年96.7%;无移植物移位,移植物肢体血栓率1.14%。

要点

  • 解剖固定式一体分叉设计EVAR长期临床成功率高,5年97.7%、10年96.7%
  • 该设计无移植物移位,肢体血栓率仅1.14%
  • 糖尿病及钙化血栓性髂动脉入路与长期临床成功降低相关

核心结论

  • 解剖固定式EVAR长期安全、可行且有效预防AAA破裂,但总生存仍受心血管事件影响。
  • 一体分叉原始设计使移植物血栓率极低,并将移位及相关再干预风险降为零。

研究设计与样本

  • 单中心回顾性队列研究,纳入1999至2016年择期治疗的623例患者,随访至2020年。
  • 随访方案包括3个月内至少一次CTA,以及每年双功超声和临床检查。
  • 主要结局为技术成功、临床成功和生存;次要结局包括免于晚期开放转换、再干预和内漏的生存。

主要发现

  • 中位年龄74±11岁,随访93±54个月。
  • 技术成功99.4%,30天临床成功98.4%,5年临床成功97.7%,10年96.7%。
  • 1、5、10、15年总生存分别为92.4%、79.5%、64.9%、45.5%。
  • AAA相关死亡6例(0.98%),其中3例为内移植物感染、3例为继发破裂。
  • 晚期开放转换9例(1.47%);1、5、10、15年免于再干预生存分别为88.4%、78.0%、76.2%、74.6%。

临床怎么用

  • 解剖固定式一体分叉EVAR可作为择期AAA的长期有效选择,尤其关注移位和肢体血栓风险较低。
  • 对合并糖尿病或钙化血栓性髂动脉入路的患者,应加强长期随访以监测临床成功降低的可能。

局限性

  • 单中心回顾性设计可能限制结果外推。
  • 择期治疗人群且未报告非择期或非解剖固定式对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The introduction of new endograft models improved long-term results of abdominal aortic aneurysm (AAA) endovascular repair (EVAR), but most of them maintained an old and unchanged design: a short body and long legs shifting up the flow divider. This study assessed the long-term results of EVAR with unimodular endoprosthesis fixed at the aorto-iliac bifurcation (Anatomical FiXation), in a large, unselected cohort. MATERIALS AND METHODS: In a single-center, retrospective cohort study, 623 patients selectively treated between 1999 and 2016, were analyzed. Follow-up protocol included at least a computed tomography angiography within 3 months and a duplex ultrasound and clinical exam yearly. All enrolled patients were analyzed by 2020. The primary outcomes were technical success, clinical success, and survival. Secondary outcomes included survival-free from late-open-conversion (LOC), reintervention, and endoleaks. RESULTS: Median age was 74±11 years and the follow-up 93±54 months. The technical success was achieved in 99.4% and the 30-day clinical success was 98.4%. A 5-year clinical success of 97.7% was registered and at 10 years success was 96.7%. The overall survival at 1, 5, 10, and 15 years was 92.4%, 79.5%, 64.9%, and 45.5%, respectively. Six (0.98%) AAA-related death were registered, 3 caused by infection of the endograft and 3 for secondary rupture. LOCs were 9 (1.47%) and reintervention-free survival at 1, 5, 10, and 15 years were 88.4%, 78.0%, 76.2%, and 74.6%, respectively. Freedom from endoleaks was 88.8% at 1 year and 72.7% at 15 years. A total of 63 high-flow endoleaks were registered (43 type I, 7 type IIIa, 12 type IIIb, and 1 type Ib+IIIb). No migrations were recorded, and the graft limb thrombosis rate was 1.14%. From a multivariate analysis resulted that long-term clinical success appeared to be reduced in patients affected by diabetes [odds ratio (OR) 0.24; p=0.04] and in presence of calcified and thrombotic iliac accesses (OR 0.16; p=0.006). CONCLUSION: EVAR with the Anatomical FiXation was confirmed to be safe, feasible, and effective to prevent AAA rupture in the long term as well. However, the overall survival remains afflicted by cardiovascular accident. The original concept of unibody bifurcated design allowed a very low rate of graft thrombosis and zeroed the risk of migration and related reintervention.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Gennai S, Andreoli F, Saitta G, et al. Two Decades of Abdominal Aortic Endovascular Repair With the Anatomical FiXation at the Aortic Bifurcation in a Large Single-Center Experience. J Endovasc Ther. 2021. PMID: 34278808. doi:10.1177/15266028211030537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。